Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Laura M SpringAndrzej NiemierkoStephanie HaddadMegan YuenAmy ComanderKerry ReynoldsJennifer ShinAtul BahnElena BrachtelMichelle SpechtBarbara L SmithAlphonse TaghianRachel JimenezJeffrey PeppercornSteven J IsakoffBeverly MoyAditya Bardia

Published in: Breast cancer research and treatment (2018)

Pertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer. Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer.

Keyphrases

rectal cancer
open label
locally advanced
lymph node
randomized controlled trial
epidermal growth factor receptor
systematic review
squamous cell carcinoma
clinical trial
metastatic breast cancer
replacement therapy